TRMT112: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: TRMT112

NCBI ID: G51504

TRMT112

TRMT112: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

TRMT112 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study and develop new treatments.

TRMT112 is a RNA molecule that is found in most tissues and cells in the body. It is a key player in the regulation of gene expression and has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis.

One of the key features of TRMT112 is its structure. It is a small molecule that is composed of only 18 amino acids and has a unique five-membered ring structure. This structure makes it distinct from other RNA molecules and has led to a lot of interest in its biology.

TRMT112 has also been shown to play a role in the regulation of gene expression. Studies have shown that it can interact with various proteins and can also act as a scaffold to recruit other RNA molecules to its surface. This interaction with other molecules has led to the possibility that TRMT112 could be a useful drug target.

Another potential mechanism by which TRMT112 could be used as a drug target is its role in the regulation of cellular processes that are associated with various diseases, including cancer. Studies have shown that TRMT112 can be overexpressed in various cancer cells and that this increase in expression can lead to the development of cancer. Additionally, TRMT112 has also been shown to play a role in the regulation of cellular apoptosis, which is a process that is involved in cell death. Overexpression of TRMT112 has been shown to promote cellular apoptosis in various cancers cells.

TRMT112 has also been shown to have potential as a biomarker for various diseases. Its expression has been shown to be regulated in various diseases, including cancer, and can be used as a biomarker for these diseases. This makes TRMT112 an attractive target for researchers to develop new diagnostic tests and treatments for these diseases.

In conclusion, TRMT112 is a non-coding RNA molecule that has a unique structure and biology. Its potential as a drug target and biomarker has led to a lot of interest in its study and development. Further research is needed to fully understand its biology and its potential as a drug.

Protein Name: TRNA Methyltransferase Activator Subunit 11-2

Functions: Acts as an activator of both rRNA/tRNA and protein methyltransferases (PubMed:25851604, PubMed:18539146, PubMed:20308323, PubMed:25851604, PubMed:31328227, PubMed:31636962, PubMed:31061526). Together with methyltransferase BUD23, methylates the N(7) position of a guanine in 18S rRNA (PubMed:25851604). The heterodimer with N6AMT1/HEMK2 catalyzes N5-methylation of ETF1 on 'Gln-185', using S-adenosyl L-methionine as methyl donor (PubMed:18539146, PubMed:31636962, PubMed:31061526). The heterodimer with N6AMT1/HEMK2 also monomethylates 'Lys-12' of histone H4 (H4K12me1) (PubMed:31061526). The heterodimer with ALKBH8 catalyzes the methylation of 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in target tRNA species (PubMed:20308323). Together with methyltransferase THUMPD3, catalyzes the formation of N(2)-methylguanosine at position 6 in a broad range of tRNA substrates and at position 7 of tRNA(Trp) (PubMed:34669960). Involved in the pre-rRNA processing steps leading to small-subunit rRNA production (PubMed:25851604). Together with methyltransferase METTL5, specifically methylates the 6th position of adenine in position 1832 of 18S rRNA (PubMed:33428944, PubMed:35033535, PubMed:31328227)

The "TRMT112 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRMT112 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets